Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
← catalyst calendarNCT06236438 · readout ≤ 1,899 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
840estimated
Sites
61
Countries
Australia, Belgium, Chile +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-10 | actual | When the study began enrolling |
| Primary completion | Oct 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Interventions
- Drug: Livmoniplimab — also filed as ABBV-151
- Drug: Budigalimab — also filed as ABBV-181
- Drug: Pembrolizumab
- Drug: Pemetrexed
- Drug: Cisplatin
- Drug: Carboplatin
- Drug: Carboplatin
Primary outcomes
what the primary-completion date above is the date OFStage 1: Best Overall Response (BOR) of Complete Response (CR)/Partial Response (PR)
measured Up to 21 Months
Stage 2: Overall Survival (OS)
measured Up to 55 Months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed